drugset
drugset / Trial / NCT04160260

Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

NCT04160260 ↗

Phase 1 Completed 18 enrolled Paratek Pharmaceuticals Inc
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.

Timeline

Start
2019-11-28
Primary completion
2020-03-23
Completion
2020-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Omadacycline Small molecule — Oral

Indications

bacterial pneumonia